Filip Janku

Insider Reports History

Location
Boston, MA
Signature
/s/ Markus Warmuth, Attorney-in-Fact
All insider transactions
Transactions in reports broken out by “transaction date” reported in original SEC filing, see here for transactions aggregated across transaction date

Holdings reported by Filip Janku:

Company Role Class Num Shares Value Price $ Report Date Ownership
Monte Rosa Therapeutics, Inc. Chief Medical Officer Common Stock 75,026 $1,138,144 $15.17 05 Jan 2026 Direct
Monte Rosa Therapeutics, Inc. Chief Medical Officer Stock Option (Right to Buy) 139,000 02 Jan 2026 Direct

Insider Reports Filed by Filip Janku

Symbol Company Period Transactions Value $ Form Type Role Filing Time
GLUE Monte Rosa Therapeutics, Inc. 02 Jan 2026 3 -$47,861 4 Chief Medical Officer 05 Jan 2026, 16:04
GLUE Monte Rosa Therapeutics, Inc. 02 Jan 2025 2 $0 4 Chief Medical Officer 06 Jan 2025, 16:15
GLUE Monte Rosa Therapeutics, Inc. 13 Sep 2024 1 $0 4 Chief Medical Officer 13 Sep 2024, 16:30
GLUE Monte Rosa Therapeutics, Inc. 02 Jan 2024 1 $0 4 Chief Medical Officer 04 Jan 2024, 16:15
GLUE Monte Rosa Therapeutics, Inc. 03 Jan 2023 1 $0 4 Chief Medical Officer 04 Jan 2023, 15:30
GLUE Monte Rosa Therapeutics, Inc. 15 Dec 2022 1 $0 4 Chief Medical Officer 19 Dec 2022, 15:42
GLUE Monte Rosa Therapeutics, Inc. 31 Oct 2022 1 $0 4 Chief Medical Officer 01 Nov 2022, 16:30
GLUE Monte Rosa Therapeutics, Inc. 01 Mar 2022 1 $0 4 Chief Medical Officer 02 Mar 2022, 17:46
GLUE Monte Rosa Therapeutics, Inc. 23 Jun 2021 1 $0 4 Chief Medical Officer 25 Jun 2021, 17:00
GLUE Monte Rosa Therapeutics, Inc. 23 Jun 2021 0 $0 3 Chief Medical Officer 23 Jun 2021, 20:43